Navigation Links
Optimer Pharmaceuticals Provides Update on DIFICID® (fidaxomicin) Tablets Launch
Date:1/9/2012

SAN DIEGO, Jan. 9, 2012 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today provided an update on commercial sales of DIFICID® (fidaxomicin) tablets since launching the antibacterial drug in July 2011 for the treatment of Clostridium difficile associated-diarrhea (CDAD) in adults 18 years of age or older in the United States.

(Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO )

"Sales of DIFICID in the United States over the past five and a half months reflect the strong initial demand for a new antibacterial drug providing a superior sustained clinical response through 25 days after the end of treatment for CDAD. Wholesale level shipments in the fourth quarter of 2011 increased almost 87% compared to the third quarter, drawing down wholesaler inventory levels," said Pedro Lichtinger, President and CEO of Optimer. "We also observed continued strong month over month growth through the fourth quarter of about 11%."

For the three months ended December 31, 2011, Optimer estimates 4,675 DIFICID treatments were shipped from Optimer's wholesalers to hospital pharmacies, retail pharmacies and long-term care facilities, exceeding treatments sold by Optimer to its wholesalers over the same period. This is an increase of 86.6% when compared to the 2,505 treatments shipped from Optimer's wholesalers to hospital pharmacies, retail pharmacies and long-term care facilities for the period of July 19, 2011 through September 30, 2011. DIFICID treatments shipped from Optimer's wholesalers to hospital pharmacies, retail pharmacies and long-term care facilities grew at a compounded monthly growth rate of 11.3% for the quarter ended December 31, 2011.

Optimer recognizes product sales of DIFICID upon delivery of product to its wholesalers. For the period of July 19,
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Optimer Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
2. Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
3. Optimer Pharmaceuticals to Present at BioCentury Newsmakers Conference
4. Optimer Pharmaceuticals and Astellas Receive Positive Opinion from CHMP for European Approval of DIFICID™
5. Optimer to Provide DIFICID™ Launch Update at Morgan Stanley Global Healthcare Conference
6. Optimer Pharmaceuticals DIFICID Featured in 11 Presentations at 51st ICAAC
7. Optimer Pharmaceuticals to Present at September 2011 Investor Conferences
8. Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
9. Clinical Infectious Diseases Publishes Subgroup Analysis Showing Optimers DIFICID™ (fidaxomicin) Tablets Exhibited Higher Clinical Cure and Global Cure Rates Than Vancomycin in Patients with Clostridium difficile-Associated Diarrhea (CDAD) Receivin
10. Optimer Pharmaceuticals Reports Second Quarter 2011 Financial Results
11. Optimer Launches DIFICID™ (fidaxomicin) Tablets for Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) in Patients 18 Years of Age and Older
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)...  Decision Resources Group finds that the laparoscopic device ... will increase to a value of over $4.3 billion ... in the large direct energy device market. In particular, ... due to the advantages they offer and as new ... Decision Resources Group,s coverage of the U.S. laparoscopic device ...
(Date:12/19/2014)... KANSAS CITY, Kan. , Dec. 18, 2014 ... PETX ), a biopharmaceutical company focused on ... for companion animals, today announced positive results from ... company,s innovative drug for treating pain in dogs ... demonstrated improvements in pain assessment scores that were ...
(Date:12/17/2014)... 2014 Revenue and earnings above the ... and development In the past 2013/14 fiscal year ... percent to EUR 4.287 billion (last year: EUR 4.190 billion) ... to EUR 360 million. "Overall, 2013/14 was a successful fiscal ... , President and CEO of Carl Zeiss AG. "Thanks to ...
Breaking Medicine Technology:U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 2U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5ZEISS Asserts its Position in Difficult Environment 2
... grants Company extension to address remaining questions on Marketing ... ... Pharma, Inc.,(Nasdaq: IDMI ) today announced that the Company ... (CHMP), the scientific,committee of the European Medicines Evaluation Agency (EMEA), ...
... for study, DENVER, Jan. 24 Regenerative ... a patient,s own stem cells to,regenerate bone and ... its,patent pending processes to treat tendon injuries., ... severe tennis,elbow, partial rotator cuff tears or Achilles ...
Cached Medicine Technology:IDM Pharma Announces Non-Binding Opinion of the European Committee for Medicinal Products for Human Use (CHMP) that Mifamurtide (L-MTP-PE) Provides a Possible Clinical Benefit in Survival 2IDM Pharma Announces Non-Binding Opinion of the European Committee for Medicinal Products for Human Use (CHMP) that Mifamurtide (L-MTP-PE) Provides a Possible Clinical Benefit in Survival 3IDM Pharma Announces Non-Binding Opinion of the European Committee for Medicinal Products for Human Use (CHMP) that Mifamurtide (L-MTP-PE) Provides a Possible Clinical Benefit in Survival 4IDM Pharma Announces Non-Binding Opinion of the European Committee for Medicinal Products for Human Use (CHMP) that Mifamurtide (L-MTP-PE) Provides a Possible Clinical Benefit in Survival 5New Non-Surgical Stem-Cell Procedure to Relieve Chronic Tendon Problems 2
(Date:12/17/2014)... (PRWEB) December 17, 2014 This ... private practices that have made outstanding and innovative ... support and progression of private practice physical therapy ... Physical Therapy Association. , On behalf of Performance ... owner and CEO of Performance accepted the award ...
(Date:12/17/2014)... A group of 127 scientists sent an “open ... to a recent statement by the center that was highly ... the efficacy of all brain exercises. , Signatories to the ... the center’s statement critical of brain exercise companies that overstate ... its case, in a document it had entitled “A Consensus ...
(Date:12/17/2014)... (PRWEB) December 17, 2014 No matter ... been able to eradicate the head louse parasite—a common ... for parents. Each year between six and twelve million ... the Miami-based lice removal treatment company comes to the ... and environmentally friendly. With its track record of customer ...
(Date:12/17/2014)... 17, 2014 Project Veritas is releasing ... videos of MIT economist and Obamacare architect Jonathan Gruber ... O’Keefe conducted the interview, which is being distributed on ... was intentional mislabeling in the Affordable Care Act in ... A two-hundred-and-fifty billion dollar per year tax grab. , ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, 2014 (HealthDay ... phenomenon is when an illness that originated in animals jumps ... -- is not uncommon and keeps researchers on their toes ... make inroads into the human population. A new report ... in this case were guinea pigs. More specifically, they were ...
Breaking Medicine News(10 mins):Health News:Performance Physical Therapy Awarded with Jayne L. Snyder Private Practice of the Year 2014 2Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 2Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 3Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 4Health News:Lice Troopers Announces New Lice Treatment Clinic in Coral Gables to Service Key Biscayne, Coconut Grove, Kendall, Brickell & South Miami 2Health News:Project Veritas: James O’Keefe Interviews the Man Who Discovered Jonathan Gruber Videos 2Health News:Guinea Pigs Can Be Source of Serious Strep Infection 2Health News:Guinea Pigs Can Be Source of Serious Strep Infection 3
... May 5 Today marks the launch of the ... network designed to focus exclusively on hospice and palliative ... their families worldwide need palliative care and support each ... cent actually receive it. The need for palliative care ...
... project entitled ,Good Practice in Traditional Chinese Medicine Research ... status of Traditional Chinese Medicine (TCM) research, identify problems ... as well as providing a forum for the exchange ... EU and China. , The three-year project ...
... Increase Hispanic Family Physicians in California LOS ANGELES and ... a $2 million grant to the David Geffen School ... , to expand its International Medical Graduate Program. The ... to serving California,s vulnerable communities and need to pass ...
... (NYSE: BSX ) is scheduled to participate ... Health Care Conference.Jim Tobin, President and Chief Executive Officer, ... beginning at approximately 9:20 a.m. E.T. Following the ... Officer will join Mr. Tobin in a question and ...
... With a Donation, TooNEW YORK, May 5 Honk if you,re ... their wheels trying to think of the perfect Mother,s Day gift, ... to make a unique gift -- one that may save lives ... You can use this traditional time of love and giving to ...
... wary of finding, however , , TUESDAY, May 5 (HealthDay ... the long-sought markers that could discern which tumors are ... , The currently hot debate about the value of ... the fact that the cancer is usually so slow-growing ...
Cached Medicine News:Health News:New International Alliance Launched to Address Urgent Needs of Palliative Care Patients Worldwide 2Health News:King's-led consortium wins €1 million EU funding for Chinese medicine research 2Health News:Kaiser Permanente Grant to Expand UCLA International Medical Center Graduate Program 2Health News:Kaiser Permanente Grant to Expand UCLA International Medical Center Graduate Program 3Health News:Kaiser Permanente Grant to Expand UCLA International Medical Center Graduate Program 4Health News:Biomarkers May Predict Aggressiveness of Prostate Cancer 2Health News:Biomarkers May Predict Aggressiveness of Prostate Cancer 3
BioScrew® Bio-Absorbable Interference Screws and Delivery System Clinically equivalent to metal interference screws....
Cannulated Interference Screws...
Stryker Endoscopy offers a wide variety of small-joint arthroscopes that produce a brilliant high-resolution image without sacrificing Stryker's ultra-high tip durability....
... AMO Vitrax features a low ... maximum protection and viscosity you ... during phaco and small-incision surgery. ... maintains anterior chamber depth for ...
Medicine Products: